Roche says Ocrevus drug reduces need for walking aids for MS patients

[October 13, 2021]  ZURICH (Reuters) - Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday.

There was a 35% reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29% reduction in the 48-week progression in primary progressive MS after 8 years after starting taking the drug, it added.

(Reporting by John Revill; Editing by Kim Coghill)

[© 2021 Thomson Reuters. All rights reserved.]

Copyright 2021 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content